FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309079146> ?p ?o ?g. }

• W4309079146 endingPage "47" @default.
• W4309079146 startingPage "28" @default.
• W4309079146 abstract "Background Generalised oedema was occasionally reported associated with immune checkpoint inhibitors (ICPIs). The purpose of this study is to investigate immune-related generalised oedema (ir-GE) drug related to ICPI, through frequency, clinical and pathological characteristics, and patient's outcome. Patients and methods Objectives of the study were to report on ir-GE associated with ICPI to define frequency, associated signs and symptoms, pathological characteristics, severity, and response to corticosteroids. To be included in the study, adult patients had to have ir-GE related to ICPI with certain or likely link, without any other known causes of generalised oedema. The study design was observational, over the period 2014–2020, from pharmacovigilance databases in France, including the prospective Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie (REISAMIC) registry. Calculation of the frequency of ir-GE was restricted to the prospective REISAMIC registry. Results Over 6633 screened patients, 20 had ir-GE confirmed drug related to ICPI. Based on the prospective REISAMIC registry, the frequency of ir-GE was 0.19% of ICPI-treated patients (3 cases out of 1598 screened patients). The 20 patients with ir-GE had a median (range) age of 62 (26–81) years, most frequent tumour types were melanoma (n = 9; 45%) and lung cancer (n = 6; 30%). The most frequent localisations of oedema were peripheral (n = 17; 85%), pleural (n = 13; 65%), and peritoneal (n = 10; 50%). Polyserositis was observed in 11 (55%) patients. The median (range) weight gain per patient was 9 (2–30) kg. Associated signs and symptoms met criteria for capillary leak syndrome (n = 4; 20%), sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) (n = 3; 15%), or subcutaneous autoimmune syndrome (n = 2; 10%). Corticosteroids were administered to 15 patients; of them, 10 (67%) improved clinically after corticosteroids. Based on CTCAEV5.0, the highest severity of ir-GE was grade ≥4 in 11 (55%) patients and four (20%) patients died due to ir-GE. Conclusions Generalised immune system-related oedema is a new category of adverse event with immune checkpoint inhibitors and is often associated with a life-threatening condition. The pathophysiology may in some cases be related to endothelial dysfunctions, such as SOS/VOD or capillary leak syndrome." @default.
• W4309079146 created "2022-11-21" @default.
• W4309079146 creator A5009254740 @default.
• W4309079146 creator A5010033165 @default.
• W4309079146 creator A5013187568 @default.
• W4309079146 creator A5015829616 @default.
• W4309079146 creator A5024442449 @default.
• W4309079146 creator A5025478490 @default.
• W4309079146 creator A5030174263 @default.
• W4309079146 creator A5034248267 @default.
• W4309079146 creator A5034842529 @default.
• W4309079146 creator A5037089481 @default.
• W4309079146 creator A5041514719 @default.
• W4309079146 creator A5046970380 @default.
• W4309079146 creator A5053154832 @default.
• W4309079146 creator A5056132643 @default.
• W4309079146 creator A5057390735 @default.
• W4309079146 creator A5058986182 @default.
• W4309079146 creator A5059436060 @default.
• W4309079146 creator A5060675099 @default.
• W4309079146 creator A5060793722 @default.
• W4309079146 creator A5065206480 @default.
• W4309079146 creator A5067624116 @default.
• W4309079146 creator A5068648444 @default.
• W4309079146 creator A5074162105 @default.
• W4309079146 creator A5075947978 @default.
• W4309079146 creator A5082291642 @default.
• W4309079146 creator A5082984172 @default.
• W4309079146 creator A5085234192 @default.
• W4309079146 creator A5086950427 @default.
• W4309079146 creator A5089551729 @default.
• W4309079146 date "2023-01-01" @default.
• W4309079146 modified "2023-10-17" @default.
• W4309079146 title "Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors" @default.
• W4309079146 cites W1996475570 @default.
• W4309079146 cites W2013720729 @default.
• W4309079146 cites W2014008304 @default.
• W4309079146 cites W2048818389 @default.
• W4309079146 cites W2059353285 @default.
• W4309079146 cites W2085752173 @default.
• W4309079146 cites W2122052232 @default.
• W4309079146 cites W2122712927 @default.
• W4309079146 cites W2265285917 @default.
• W4309079146 cites W2289841322 @default.
• W4309079146 cites W2295805773 @default.
• W4309079146 cites W2327056122 @default.
• W4309079146 cites W2462936585 @default.
• W4309079146 cites W2485473798 @default.
• W4309079146 cites W2510390828 @default.
• W4309079146 cites W2549414845 @default.
• W4309079146 cites W2595489634 @default.
• W4309079146 cites W2784236808 @default.
• W4309079146 cites W2786816161 @default.
• W4309079146 cites W2791265590 @default.
• W4309079146 cites W2889652953 @default.
• W4309079146 cites W2903853935 @default.
• W4309079146 cites W2914657490 @default.
• W4309079146 cites W2946389970 @default.
• W4309079146 cites W2977696805 @default.
• W4309079146 cites W3009002657 @default.
• W4309079146 cites W3010785746 @default.
• W4309079146 cites W3011996558 @default.
• W4309079146 cites W3111431343 @default.
• W4309079146 cites W3127189789 @default.
• W4309079146 cites W3138816602 @default.
• W4309079146 cites W3168833419 @default.
• W4309079146 cites W3185021648 @default.
• W4309079146 cites W3203170087 @default.
• W4309079146 cites W3203358020 @default.
• W4309079146 cites W4214937426 @default.
• W4309079146 cites W4280553421 @default.
• W4309079146 doi "https://doi.org/10.1016/j.ejca.2022.11.001" @default.
• W4309079146 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36473326" @default.
• W4309079146 hasPublicationYear "2023" @default.
• W4309079146 type Work @default.
• W4309079146 citedByCount "1" @default.
• W4309079146 countsByYear W43090791462023 @default.
• W4309079146 crossrefType "journal-article" @default.
• W4309079146 hasAuthorship W4309079146A5009254740 @default.
• W4309079146 hasAuthorship W4309079146A5010033165 @default.
• W4309079146 hasAuthorship W4309079146A5013187568 @default.
• W4309079146 hasAuthorship W4309079146A5015829616 @default.
• W4309079146 hasAuthorship W4309079146A5024442449 @default.
• W4309079146 hasAuthorship W4309079146A5025478490 @default.
• W4309079146 hasAuthorship W4309079146A5030174263 @default.
• W4309079146 hasAuthorship W4309079146A5034248267 @default.
• W4309079146 hasAuthorship W4309079146A5034842529 @default.
• W4309079146 hasAuthorship W4309079146A5037089481 @default.
• W4309079146 hasAuthorship W4309079146A5041514719 @default.
• W4309079146 hasAuthorship W4309079146A5046970380 @default.
• W4309079146 hasAuthorship W4309079146A5053154832 @default.
• W4309079146 hasAuthorship W4309079146A5056132643 @default.
• W4309079146 hasAuthorship W4309079146A5057390735 @default.
• W4309079146 hasAuthorship W4309079146A5058986182 @default.
• W4309079146 hasAuthorship W4309079146A5059436060 @default.
• W4309079146 hasAuthorship W4309079146A5060675099 @default.
• W4309079146 hasAuthorship W4309079146A5060793722 @default.
• W4309079146 hasAuthorship W4309079146A5065206480 @default.

• next